Database→Mazdutide

Tier 1-2Weight LossMetabolicDiabetesPREMIUM

Mazdutide

Mazdutide (IBI362 / LY3305677 / Xinermei) - GLP-1 and Glucagon Receptor Dual Agonist

Approved in China (NMPA June 2025 obesity, September 2025 T2D) as Xinermei. Not FDA-approved or EMA-approved. Eli Lilly Phase 2 ongoing in US. FDA approval estimated 2028 to 2029.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

Mazdutide is the world's first approved dual glucagon/GLP-1 receptor agonist. GLORY-1 Phase 3 (n=610, NEJM): 14.0% mean weight loss at 48 weeks with 6 mg dose. GLORY-2 (9 mg): 20.1% weight loss. DREAMS-1 and DREAMS-2 (Nature): superiority to dulaglutide in T2D. Liver fat reduction up to 80% (MRI-PDFF). Approved in China, not FDA-approved. All Phase 3 data from exclusively Chinese populations.

🔒

Full Profile: Premium Members Only

The complete Mazdutide profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use